Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Tropicamide 0.5% and 1% single dose units
Tryptophan tablets		Specialist initiation only
Ubidecarenone
Urokinase injection		Hospital use only
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis	Hospital use only
Ustekinumab (Stelara®)	TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment TA456 - Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Vacuum pumps		Red - if not in line with the SLS criteria
Vandetanib
Varicella-zoster immunoglobulin

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.